Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,604 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of Food, Gastric Acid Reduction, and Strong CYP3A Induction on the Pharmacokinetics of Tasurgratinib, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor.
Nomoto M, Hasunuma T, Cai C, Suzuki I, Mikubo A, Funasaka S, Otake Y, Nakai K, Yasuda S. Nomoto M, et al. Among authors: yasuda s. J Clin Pharmacol. 2024 Dec;64(12):1541-1551. doi: 10.1002/jcph.6104. Epub 2024 Aug 1. J Clin Pharmacol. 2024. PMID: 39087871 Free PMC article. Clinical Trial.
Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant.
Murphy PJ, Yasuda S, Nakai K, Yoshinaga T, Hall N, Zhou M, Aluri J, Rege B, Moline M, Ferry J, Darpo B. Murphy PJ, et al. Among authors: yasuda s. J Clin Pharmacol. 2017 Jan;57(1):96-104. doi: 10.1002/jcph.785. Epub 2016 Aug 4. J Clin Pharmacol. 2017. PMID: 27338807 Clinical Trial.
Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease.
Majid O, Cao Y, Willis BA, Hayato S, Takenaka O, Lalovic B, Sreerama Reddy SH, Penner N, Reyderman L, Yasuda S, Hussein Z. Majid O, et al. Among authors: yasuda s. CPT Pharmacometrics Syst Pharmacol. 2024 Dec;13(12):2111-2123. doi: 10.1002/psp4.13224. Epub 2024 Aug 29. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 39207112 Free PMC article.
Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.
Hayato S, Takenaka O, Sreerama Reddy SH, Landry I, Reyderman L, Koyama A, Swanson C, Yasuda S, Hussein Z. Hayato S, et al. Among authors: yasuda s. CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1578-1591. doi: 10.1002/psp4.12862. Epub 2022 Sep 27. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 36165093 Free PMC article.
Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Majid O, Hayato S, Sreerama Reddy SH, Lalovic B, Hihara T, Hoshi T, Funahashi Y, Aluri J, Takenaka O, Yasuda S, Hussein Z. Majid O, et al. Among authors: yasuda s. CPT Pharmacometrics Syst Pharmacol. 2024 Jun;13(6):954-969. doi: 10.1002/psp4.13130. Epub 2024 Mar 26. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38528813 Free PMC article. Clinical Trial.
A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease.
Geerts H, Walker M, Rose R, Bergeler S, van der Graaf PH, Schuck E, Koyama A, Yasuda S, Hussein Z, Reyderman L, Swanson C, Cabal A. Geerts H, et al. Among authors: yasuda s. CPT Pharmacometrics Syst Pharmacol. 2023 Apr;12(4):444-461. doi: 10.1002/psp4.12912. Epub 2023 Jan 20. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36632701 Free PMC article.
2,604 results